{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"description":"Best biochemical response was calculated from assessments at baseline and during treatment. Responders were those patients with a best biochemical response of CR or PR, confirmed by repeat assessments, which were to be performed no less than 4 weeks after the criteria for PR or CR were first met. CR and PR being defined according to level of CTN.","groups":[{"description":"Vandetanib (300 mg daily)","id":"OG000","title":"Vandetanib 300 mg"},{"description":"Placebo daily","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Blood samples for analysis of CTN were taken at screening baseline (average of 0, 1, 4 and 8 hours), then every 4 weeks until discontinuation and 60 day follow up","title":"Biochemical Response Calcitonin (CTN)","type":"SECONDARY","unitOfMeasure":"Participants"}